Clinical trial
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who…
NCT03669588 · argenx, Industry · Completed
Key facts
| NCT number | NCT03669588 |
|---|---|
| Title | An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness |
| Acronym | ADAPT |
| Lead sponsor | argenx, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Generalized Myasthenia Gravis |
| Intervention type | Biological |
| Interventions | ARGX-113, Placebo |
| Enrollment | 167 |
| Start date | Aug 22, 2018 |
| Primary completion | Apr 6, 2020 |
| Completion | Apr 6, 2020 |
| First posted | Sep 13, 2018 |
| Last update posted | Feb 8, 2022 |
| Countries | Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland and 4 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: